finmarketnews.com
news-details
Healthcare & Biotech,Health,Health Technology,Health Services,Insiders

EDSA Showing Recent Insider Activity

Recent activity shows that Edesa Biotech, EDSA the Insider Confidence level is trending Up due to Corporate Insiders of EDSA Bought $7.2K worth of shares in the last 3 months.  

Before you dig into this report it is important to remember that "Insider Buying" is the purchase of shares in a corporation by a director, officer, or executive within the company. Insider buying is not the same as insider trading, which refers to corporate insiders making illegal stock purchases based on non-public information.
 
"Insider Buying" is not a crime when the buying is based on public information. 
 
Additionally, since insiders have unique insights into their own companies, they often gobble up shares when they believe the stock is undervalued or dump stock when it’s time to sell.  That's why people pay attention to insider buying.

Here is a list of the latest insider activity for EDSA:
  • Brooks Michael J - President, Bought $3,613 worth of shares on 1 day ago
  • Michael Brooks - President, Bought $3,622 worth of shares on 1 day ago
  • Nijhawan Pardeep - CEO,Director,>10% Owner, Bought $10,460 worth of shares on 11 months ago
  • Brooks Michael J - President, Bought $18,165 worth of shares on 11 months ago
TipRanks.com reports that Edesa Biotech currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $16.00 . The target pricing ranges from a high forecast of $16.00 down to a low forecast of $16.00. Edesa Biotech (EDSA)’s last closing price was 3.19 which would put the average price target at 401.57% upside.

In addition, TradingView issued a Sell rating for EDSA over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook

Edesa Biotech, EDSA
Summary: Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO.
  • Last Price: 3.19
  • Price Change: 0, 11.54%
  • Yearly Gain: -39.24%
  • Market Cap: 43.97M
  • P/E Ratio: -2.751
Remember, securities are volatile, so please do your own research on EDSA. If you are interest in stocks like EDSA or stocks in the Healthcare sector, please click here.

One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  Click here for more on Tipranks.com.

When an EDSA analyst reiterates coverage on stocks, we will let you know.  Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.

This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to EDSA, you should consider joining TipRanks.com.

Disclaimer:
 Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data.
Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================